This episode of This Week in Neuroscience (TWiN) reviews the neurobiological basis of overeating and the escalating global obesity epidemic, based on a 2025 Neuron article. The discussion centers on the functional and anatomical overlap between the homeostatic (energy balance) and hedonic (pleasure/reward) feeding systems. Homeostasis is governed by the hypothalamus (ARC/PVH) using signals like leptin and ghrelin. Hedonic feeding, which overrides satiety, involves the mesolimbic dopamine system (VTA/NAc). The combination of fat and sugar in palatable, calorie-dense foods strongly promotes overeating by hijacking these reward circuits. Genetic factors, ranging from rare monogenic deficiencies (e.g., leptin, POMC) to common polygenic contributions, modulate vulnerability. The current gold standard for pharmacological intervention, GLP-1 receptor agonists (e.g., Semaglutide/Ozempic), is effective in reducing appetite and weight by acting on both central and peripheral mechanisms, but side effects like anhedonia and the high potential for weight regain upon cessation necessitate long-term solutions. The concept of "food addiction" is deemed controversial and currently lacks neurobiological support, as far as the authors can tell.
The Neurobiology of Overeating (TWiN 66)
8:50 Obesity Context: The global prevalence of obesity (BMI > 30 kg/m²) is increasing, predicted to affect over half of the adult population by 2035. As far as can be determined, increased physical activity alone is insufficient to prevent or reverse established obesity (10:55).
11:09 Drivers of Overeating: Foods combining high fat and high sugar content—a combination rare in natural sources but common in ultra-processed foods—are particularly potent drivers of overeating. Exclusive ultra-processed diets increase daily caloric intake by approximately 500 kCal (13:53).
15:28 Homeostatic vs. Hedonic Systems: Feeding is regulated by two overlapping systems: the homeostatic system (maintaining energy balance) and the hedonic system (eating for pleasure/reward). Highly palatable food overrides satiety (the feeling of fullness), leading to eating when not hungry (16:16). The hedonic system may be an evolutionary adaptation to store fat for leaner times (19:44).
20:29 Homeostatic Circuits: Central regulation occurs in the medial hypothalamus, specifically the Arcuate Nucleus (ARC) and Paraventricular Nucleus (PVH).
ARC neurons (AGRP) promote feeding when hungry (stimulated by ghrelin, secreted by the stomach) and are inhibited by satiety signals (leptin from adipose tissue, insulin from the pancreas) (21:19, 24:49).
Leptin deficiency (a rare monogenic condition, ~1 in 1 million) causes constant hunger and massive overeating (29:03, 51:10).
35:11 Hedonic Circuits: These are centered around the Lateral Hypothalamic Area (LHA) and the mesolimbic dopamine system (VTA and Nucleus Accumbens/NAc). LHA neurons disinhibit VTA dopamine neurons, driving the consumption of palatable foods (36:14).
Dopamine release in the NAc is triggered by food cues (sight, smell, taste) and promotes eating beyond physiological need (41:30). This dopamine signal is hypothesized to drive learning about food reward associations (37:22, 40:00).
Stimulating the NAc-LHA axis instantly stops feeding, suggesting its critical role in controlling intake exceeding metabolic needs (45:27).
49:02 Homeostatic-Hedonic Crosstalk: The systems are intertwined; for example, POMC neurons yield beta-endorphin, which acts on μ opioid receptors (μORs) in the NAc. Blocking these μORs reduces sweet food consumption specifically, without affecting consumption of normal chow (50:12).
58:01 Genetic Basis: Obesity can be monogenic (rare, high effect size, often affecting leptin/MC4R) or polygenic (common, hundreds of small-effect polymorphisms adding up) (58:15).
1:05:09 Food Addiction: Overeating shares features with drug addiction (compulsion, loss of control, involvement of dopamine), but the concept of "food addiction" is rejected by many researchers, as it is not currently empirically supported by neurobiological investigation (1:07:45).
1:07:59 Pharmacological Treatments: GLP-1 receptor (GLP-1R) agonists (e.g., Semaglutide/Ozempic) are highly effective, achieving 15%–20% weight loss (1:11:49).
Mechanism: They target GLP-1 receptors on ARC/POMC neurons to suppress appetite and slow gastric emptying to prolong fullness (1:12:35).
Side effects include loss of muscle mass, depression, and anhedonia (reduced ability to experience pleasure) (1:13:05).
The efficacy is typically transient; patients often regain weight upon discontinuing treatment, reflecting the difficulty of sustained behavioral change (1:17:07).
1:19:04 Societal Factors: The environment heavily influences intake (e.g., large portion sizes and easily accessible sugary drinks in Western culture vs. smaller portions in Japan) (1:19:04).